U.S., Jan. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07312630) titled 'Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies' on Sept. 29, 2025.
Brief Summary: Evaluate the safety, pharmacokinetic (PK) characteristics, and pharmacodynamic (PD) characteristics of LV009 injection in subjects with relapsed/refractory CD19-positive hematologic malignancies.
Study Start Date: Sept. 25, 2025
Study Type: INTERVENTIONAL
Condition:
Non-Hodgkin Lymphoma (NHL)
Acute Lymphoblastic Leukemia (ALL), Adult
Intervention:
BIOLOGICAL: LV009 Injection Infusion
A dose escalation was conducted using four fixed doses of LV009 injection solution: 0...